中国药王又“卖”了!四巨头集体“失血”,国药、华润都撑不住了?

E药经理人
Nov 06

11月4日,一笔长达十年的合作协议让沉默已久的血液制品行业重新成为焦点。全球血液制品巨头杰特贝林与百洋医药签署合作协议,百洋获得其人血白蛋白安博美在中国大陆特定市场的推广与经销权,其中前三年最低采购量分别为450万瓶、500万瓶和550万瓶。同一时间,行业另一端却在经历“失血”。国内血制品赛道中的天坛生物、博雅生物、上海莱士、派林生物等几家龙头企业,在2025年三季报中齐刷刷交出一份疲软答卷:营收...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10